---
title: "Standard BioTools Inc. (LAB.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/LAB.US.md"
symbol: "LAB.US"
name: "Standard BioTools Inc."
industry: "Life Sciences Tools and Services"
---

# Standard BioTools Inc. (LAB.US)

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Location | US Market |
| Website | [www.standardbio.com](https://www.standardbio.com) |

## Company Profile

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operate...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-16T04:30:12.000Z

**Overall: C (0.47)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 33 / 62 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 79.77% |  |
| Net Profit YoY | 24.82% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.08 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 430.71M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 169.74M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -33.26% | E |
| Profit Margin | -75.56% | E |
| Gross Margin | 48.51% | B |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 79.77% | A |
| Net Profit YoY | 24.82% | B |
| Total Assets YoY | -20.82% | E |
| Net Assets YoY | -18.33% | E |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -132.35% | D |
| OCF YoY | 79.77% | A |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.28 | D |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 25.94% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Standard BioTools Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-33.26%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-75.56%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "48.51%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "79.77%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "24.82%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-20.82%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-18.33%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-132.35%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "79.77%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.28",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "25.94%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ChromaDex (US.CDXC) | A | A | A | B | B | A |
| 02 | Agilent Tech (US.A) | A | C | B | C | C | B |
| 03 | Waters (US.WAT) | A | B | B | C | C | B |
| 04 | WuXi Biologics (US.WXXWY) | B | B | D | A | B | B |
| 05 | West Pharmaceutical (US.WST) | B | B | B | B | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.36 | 39/59 | - | - | - |
| PB | 1.08 | 17/59 | 1.24 | 1.13 | 0.92 |
| PS (TTM) | 2.54 | 21/59 | 3.13 | 2.84 | 2.48 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-30T05:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 33% |
| Overweight | 0 | 0% |
| Hold | 2 | 67% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.12 |
| Highest Target | 1.75 |
| Lowest Target | 1.35 |

## References

- [Company Overview](https://longbridge.com/en/quote/LAB.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/LAB.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/LAB.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
